MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib

BACKGROUND: The immune microenvironment within hepatocellular carcinoma (HCC) is remarkably intricate. Although the combination of an immune checkpoint inhibitor and Lenvatinib can extend the overall survival of HCC patients, the outcome remains suboptimal. METHODS: We assessed alterations in MEX3C...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jinhui, Zhao, Jie, Xu, Qiuran, Huang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568896/
https://www.ncbi.nlm.nih.gov/pubmed/37828435
http://dx.doi.org/10.1186/s12885-023-11320-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568896/
https://www.ncbi.nlm.nih.gov/pubmed/37828435
http://dx.doi.org/10.1186/s12885-023-11320-4

Ejemplares similares